Management of secondary hyperparathyroidism in peritoneal dialysis patients

doi:10.3877/cma.j.issn.2095-3216.2016.03.004

Abstract

Abstract:

Secondary hyperparathyroidism (SHPT) is a common complication of chronic kidney disease. And along with calcium and phosphorus metabolic disorders, SHPT play a serious impact on bone metabolism, cardiovascular and soft tissue calcification in dialysis patients, reducing the patients′ life quality, and increasing the mortality. For continuous ambulatory peritoneal dialysis (CAPD) patients, there are various factors influencing calcium, phosphorus, and PTH metabolism, including diet, residual renal function, peritoneal transport characteristics, dialysate calcium concentration, and phosphate-binding drugs. Early diagnosis and appropriate treatment are still important measurers to delay these complications. The main treatment for SHPT includes medicine and parathyroidectomy. At present in our country, activated vitamin D, calcium agent, cinacalet, and AMG 416, a novel peptide agonist for the calcium-sensing receptor, have manifested better clinical efficacy. Parathyroidectomy has been mainly used for treating refractory SHPT, including subtotal parathyroidectomy and total parathyroidectomy plus autotransplantation.

Key words: Peritoneal dialysis, Secondary hyperparathyroidism, Treatment

Zhiyong Guo, Lu Li. Management of secondary hyperparathyroidism in peritoneal dialysis patients[J]. Chinese Journal of Kidney Disease Investigation(Electronic Edition), 2016, 05(03): 108-113.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhsbyjdzzz.cma-cmc.com.cn/EN/10.3877/cma.j.issn.2095-3216.2016.03.004

https://zhsbyjdzzz.cma-cmc.com.cn/EN/Y2016/V05/I03/108

References 55

[1]	Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD)[J]. Kidney Int, 2009, 76(Suppl 113): S50-S99.
[2]	Couttenye MM,D′Haese PC,Van Hoof VO, et al. Low serum levels of alkaline phosphatase of bone origin: a good marker of adynamic bone disease in haemodialysis patients[J]. Nephrol Dial Transplant, 1996, 11(6): 1065-1072.
[3]	Brandenburg VM,Ketteler M,Rodriguez M. Ten years of progress in our understanding of uremic vascular calcification and disease: a decade summarized in 20 steps[J]. Kidney Int Suppl, 2011, 1(4): 116-121.
[4]	Goodman WG,London G,Amann K, et al. Vascular calcification in chronic kidney disease[J]. Am J Kidney Dis, 2004, 43(3): 572-579.
[5]	Demer LL,Tintut Y. Vascular calcification: pathobiology of multifaceted disease[J]. Circulation, 2008, 117(22): 2938-2948.
[6]	Moe SM,Chen NX. Pathophysiology of vascular calcification in chronic kidney disease[J]. Circ Res, 2004, 95(6): 560-567.
[7]	Shioi A,Nishizawa Y. Vascular calcification in chronic kidney disease: pathogenesis and clinical implications[J]. J Ren Nutr, 2009, 19(1): 78-81.
[8]	Brandi L. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis[J]. Dan Med Bull, 2008, 55(4): 186-210.
[9]	Koizumi M,Komaba H,Fukagawa M. Parathyroid function in chronic kidney disease: role of FGF23-Klotho axis[J]. Contrib Nephrol, 2013, 180: 110-123.
[10]	Goodman WG,Quarles LD. Development and progression of secondary hyperparathyroidism in chronic kidney disease: lessons from molecular genetics[J]. Kidney Int, 2008, 74(3): 276-288.
[11]	Mendoza FJ,Lopez I,Canalejo R, et al. Direct upregulation of parathyroid calcium-sensing receptor and vitamin D receptor by calcimimetics in uremic rats[J]. Am J Physiol Renal Physiol, 2009, 296(3): F605-F613.
[12]	Cozzolino M,Lu Y,Finch J, et al. p21(WAF1) and TGF-alpha mediate parathyroid growth arrest by vitamin D and high calcium[J]. Kidney Int, 2001, 60(6): 2109-2117.
[13]	Chudek J,Ritz E,Kovacs G. Genetic abnormalities in parathyroid nodules of uremic patients[J]. Clin Cancer Res, 1998, 4(1): 211-214.
[14]	Drueke TB,Massy ZA. Changing bone patterns with progression of chronic kidney disease[J]. Kidney Int, 2016, 89(2): 289-302.
[15]	Malluche HH,Mawad HW,MonierFaugere MC. Renal osteodystrophy in the first decade of the new millennium: Analysis of 630 bone biopsies in black and white patients[J]. J Bone Miner Res, 2011, 26(6): 1368-1376.
[16]	Block GA,Klassen PS,Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis[J]. J Am Soc Nephrol, 2004, 15(8): 2208-2218.
[17]	Moe SM,Drueke TB. Management of secondary hyperparathyroidism: the importance and the challenge of controlling parathyroid hormone levels without elevating calcium, phosphorus, and calcium-phosphorus product[J]. Am J Nephrol, 2003, 23(6): 369-379.
[18]	Tentori F,Blayney MJ,Albert JM, et al. Mortality risk for dialysis patients with different levels of serum calcium, phosphorus, and PTH: the Dialysis Outcomes and Practice Patterns Study (DOPPS)[J]. Am J Kidney Dis, 2008, 52(3): 519-530.
[19]	Floege J. Calcium-containing phosphate binders in dialysis patients with cardiovascular calcifications: should we CARE-2 avoid them?[J]. Nephrol Dial Transplant, 2008, 23(10): 3050-3052.
[20]	Barreto FC,Barreto DV,Moyses RM, et al. K/DOQI-recommended intact PTH levels do not prevent low-turnover bone disease in hemodialysis patients[J]. Kidney Int, 2008, 73(6): 771-777.
[21]	Cohen-Solal ME,Boudailliez B,Sebert JL, et al. Comparison of intact, mid region and carboxyterminal assays of parathyroid hormone for the diagnosis of bone disease in hemodialyzed patients[J]. J Clin Endocrinol Metab, 1991, 73(3): 516-524.
[22]	Quarles LD,Lobaugh B,Murphy G. Intact parathyroid hormone overestimates the presence and severity of parathyroid-mediated osseous abnormalities in uremia[J]. J Clin Endocrinol Metab, 1992, 75(1): 145-150.
[23]	Wang M,Hercz G,Sherrard DJ, et al. Relationship between intact 1-84 parathyroid hormone and bone histomorphometric parameters in dialysis patients without aluminium toxicity[J]. Am J Kidney Dis, 1995, 26(5): 836-844.
[24]	Bellasi A,Feramosca E,Muntner P, et a1. Correlation of simple imaging tests and coronary artery calcium measured by computed tomography in hemodialysis patients[J]. Kidney Int, 2006, 70(9): 1623-1628.
[25]	Bender FH,Bernardini J,Piraino B. Calcium mass transfer with dialysate containing 1.25 and1.75 mmol/L calcium in peritoneal dialysis patients[J]. Am J Kidney Dis, 1992, 20(4): 367-371.
[26]	Weinreich T,Ritz E,Passlick-Deetjen J. Long-term dialysis with low-calcium solution (1.0 mmol/L) in CAPD: Effects on bone mineral metabolism[J]. Pert Dial Int, 1996, 16(3): 260-268.
[27]	Brandi L,Melsen PK,Bro S, et a1. Long-term effects of intermittent oral alphacalcidol, calcium carbonate and low-calcium dialysis (1.25 mmol/L) on secondary hyperparathyroidism in patients on CAPD[J]. J Inter Med, 1998, 244(2): 121-131.
[28]	Amstrong A,Beer J,Noonan K, et a1. Reduced calcium dialysate in CAPD patients: Eficacy and limitations[J]. Nephrol Dial Transplant, 1997, 12(6): 1223-1228.
[29]	Katopodis KP,Koliousi EL,Andrikos EK, et al. Magnesium homeostasis in patients undergoing continuous ambulatory peritoneal dialysis: role of the dialysate magnesium concentration[J]. Artif Organs, 2003, 27(9): 853-857.
[30]	Navarro JF,Mora C,Garcia J, et al. Hypermagnesemia in continuous ambulatory peritoneal dialysis patients[J]. Perit Dial Int, 1998, 18(1): 77-80.
[31]	Cho MS,Lee KS,Lee YK, et al. Relationship between the serum parathyroid hormone and magnesium levels in continuous ambulatory peritoneal dialysis (CAPD) patients using low-magnesium peritoneal dialysate[J]. Korean J Intern Med, 2002, 17(2): 114-121.
[32]	Mehrotra R,Kermah DA,Salusky IB, et al. Chronic kidney disease, hypovitaminosis D and mortality in the United States[J]. Kidney Int, 2009, 76(9): 977-983.
[33]	Wang AY,Lam CW,Sanderson JE, et al. Serum 25-hydroxyvitamin D status and cardiovascular outcomes in chronic peritoneal dialysis patients: a 3-y prospective cohort study[J]. Am J Clin Nutr, 2008, 87: 1631-1638.
[34]	Aloni Y,Shany S,Chaimovitz C. Losses of 25-hydroxyvitamin in peritoneal fluid: possible mechanism for bone disease in uremic patients treated with chronic ambulatory peritoneal dialysis[J]. Miner Electrolyte Metab, 1983, 9(2): 82-86.
[35]	Sahin G,Kirli I,Sirgamul B, et al. Loss via peritoneal fluid as a factor for low 25(OH)D3 level in peritoneal dialysis patients[J]. Int Urol Nephrol, 2009, 41(4): 989-996.
[36]	Rodriguez-Ortiz ME,Canalejo A,Herencia C, et al. Magnesium modulates parathyroid hormone secretion and upregulates parathyroid receptor expression at moderately low calcium concentration[J]. Nephrol Dial Transplant, 2014, 29(2): 282-289.
[37]	Evenepoel P,Selgas R,Caputo F, et al. Efficacy and safety of sevelamer hydrochloride and calcium acetate in patients on peritoneal dialysis[J]. Nephrol Dial Transplant, 2009, 24(1): 278-285.
[38]	Zhai CJ,Yu XS,Sun QL, et al. Effect of lanthanum carbonate versus calcium-based phosphate binders in dialysis patients: a meta-analysis[J]. Clin Nephrol, 2014, 82(6): 372-378.
[39]	Hutchison AJ,Maes B,Vanwalleghem J, et al. Long-term efficacy and tolerability of lanthanum carbonate: results from a3-year study[J]. Nephron Clin Pract, 2006, 102(2): c61-c71.
[40]	Hutchison AJ,Barnett ME,Krause R, et al. Long-term efficacy and safety profile of lanthanum carbonate: results for up to 6 years of treatment[J]. Nephron Clin Pract, 2008, 110(1): c15-c23.
[41]	Yokoyama K,Hirakata H,Akiba T, et al. Ferric citrate for the treatment of hyperphosphatemia in nondialysis-dependent CKD[J]. Clin J Am Soc Nephrol, 2014, 9(3): 543-552.
[42]	Yokoyama K,Akiba T,Fukagawa M, et al. Long-term safety and efficacy of a novel iron-containing phosphate binder, JTT-751, in patients receiving hemodialysis[J]. J Renal Nutr, 2014, 24(4): 261-267.
[43]	Iida A,Kemmochi Y,Kakimoto K, et al. Ferric citrate, a new phosphate binder, prevents the complications of secondary hyperparathyroidism and vascular calcification[J]. Am J Nephrol, 2013, 37(4): 346-358.
[44]	Locatelli F,Spasovski G,Dimkovic N, et al. The effects of colestilan versus placebo and sevelamer in patients with CKD 5D and hyperphosphataemia: a 1-year prospective randomized study[J]. Nephrol Dial Transplant, 2014, 29(5): 1061-1073.
[45]	Eto N,Miyata Y,Ohno H, et al. Nicotinamide prevents the development of hyperphosphatemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure[J]. Nephrol Dial Transplant, 2005, 20(7): 1378-1384.
[46]	Jamaluddin EJ,Gafor AH,Yean LC, et al. Oral paricalcitol versus oral calcitriol in continuous ambulatory peritoneal dialysis patients with secondary hyperparathyroidism[J]. Clin Exp Nephrol, 2014, 18(3): 507-514.
[47]	Akizawa T,Akiba T,Hirakata H, et al. Comparison of paricalcitol with maxacalcitol injection in Japanese hemodialysis patients with secondary hyperparathyroidism[J]. Ther Apher Dial, 2015, 19(3): 225-234.
[48]	Li D,Shao L,Zhou H, et al. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis[J]. Endocrine, 2013, 43(1): 68-77.
[49]	Yamada S,Tokumoto M,Taniguchi M, et al. Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism[J]. Ther Apher Dial, 2015, 19(4): 367-377.
[50]	Hong YA,Cho YS,Kim SW, et al. Diameter of parathyroid glands measured by computed tomography as a predictive indicator for response to cinacalcet in dialysis patients with secondary hyperparathyroidism[J]. Kidney Blood Press Res, 2015, 40(3): 277-287.
[51]	Martin KJ,Bell G,Pickthorn K, et al. Velcalcetide (AMG 416), a novel peptide agonist of the calcium-sensing receptor, reduces serum parathyroid hormone and FGF23 levels in healthy male subjects[J]. Nephrol Dial Transplant, 2014, 29(2): 385-392.
[52]	Martin KJ,Pickthorn K,Huang S, et al. AMG 416 (velcalcetide) is a novel peptide for the treatment of secondary hyperparathyroidism in a single-dose study in hemodialysis patients[J]. Kidney Int, 2014, 85(1): 191-197.
[53]	Henley C 3rd,Yang Y,Davis J, et al. Discovery of a calcimimetic with differential effects on parathyroid hormone and calcitonin secretion[J]. J Pharmacol Exp Ther, 2011, 337(3): 681-691.
[54]	Neagoe RM,Mircea M,Voidǎzan S, et al. Subtotal parathyroidectomy versus total parathyroidectomy with autotransplant in secondary hyperparathyroidism, a single-centre prospective cohort of 43 patients[J]. Endokrynol Pol, 2016, 67(2): 202-209.
[55]	Yang J,Hao R,Yuan L, et al. Value of dual-phase (99m)Tc-sestamibi scintigraphy with neck and thoracic SPECT/CT in secondary hyperparathyroidism[J]. Am J Roentgenol, 2014, 202(1): 180-184.

Please choose a citation manager

Content to export